You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mantle Cell Lymphoma; Zanubrutinib; Rituximab; ASCT

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Mantle-Cell Trial in Shanghai (Zanubrutinib, Rituximab, Bendamustin)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • Shanghai, Shanghai, China
    Ruijin Hospital
Nov 14, 2023

Untreated Mantle Cell Lymphoma Trial in Suzhou (zanubrutinib and rituximab, BEAM pretreatment, zanubrutinib maintenance)

Recruiting
  • Untreated Mantle Cell Lymphoma
  • zanubrutinib and rituximab
  • +2 more
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 16, 2022

Mantle Cell Lymphoma Trial (drug, biological, other, procedure)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Jul 26, 2023

Mantle Cell Lymphoma Trial (Zanubrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Nov 22, 2022

Mantle Cell Lymphoma Trial in Miami, Houston (Zanubrutinib, Tafasitamab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Miami, Florida
  • +1 more
Aug 31, 2023

Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

Not yet recruiting
  • Mantle-cell Lymphoma
  • Polatuzumab, bendamustin und rituximab
  • (no location specified)
May 11, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma Trial in Guangzhou (Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib

Recruiting
  • Mantle Cell Lymphoma
  • Newly-diagnosed Mantle Cell Lymphoma
  • Zanubrutinib and Rituximab
  • +2 more
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • (no location specified)
May 16, 2023

Lymphoma Trial in Beijing, Shanghai City, Seoul (Obinutuzumab, Glofitamab, Rituximab)

Recruiting
  • Lymphoma
  • Beijing, China
  • +2 more
Oct 12, 2023

Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)

Not yet recruiting
  • Splenic Marginal Zone Lymphoma
  • Aarhus, Denmark
  • +4 more
Feb 17, 2023

Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Oct 31, 2022

Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus RCHOP
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 16, 2023

Recurrent Refractory Mantle Cell Lymphoma

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Peking University Third Hospital
    Aug 1, 2022

    Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • Shenyang, Liaoning, China
      Xing Xiaojing
    Jun 1, 2023

    Mantle Cell Lymphoma, Lymphoma, Mantle Cell Trial run by the NCI (EPOCH-R, GM-CSF, Idiotype vaccine)

    Completed
    Has Results
    • Mantle Cell Lymphoma
    • Lymphoma, Mantle Cell
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Jan 4, 2023

    Mantle Cell Lymphoma Trial in Guangzhou (R-CHOP/R-DHAOx; Zanubrutib(induction); ASCT conditioning ; Zanubrutinib(Maintenance))

    Recruiting
    • Mantle Cell Lymphoma
    • R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）
    • Guangzhou, Guangdong, China
      Department of Medical Oncology, Sun Yat-sen University Cancer Ce
    Aug 24, 2021

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +9 more
    • Adelaide, Australia
    • +12 more
    Jan 6, 2023

    Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)

    Not yet recruiting
    • Mantle Cell Lymphoma (MCL)
    • Duarte, California
    • +11 more
    Jul 17, 2023

    Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Marginal Zone Lymphoma
    • Westbury, New York
      Clinical Research Alliance, Inc.
    Nov 14, 2022

    Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

    Not yet recruiting
    • Primary Central Nervous System Lymphoma
    • +3 more
    • Miami, Florida
      Miami Cancer Institute at Baptist Health, Inc.
    Dec 23, 2022

    Mantle Cell Lymphoma Trial in Duarte, Ann Arbor, Columbus (Venetoclax, Lenalidomide, Rituximab)

    Active, not recruiting
    • Mantle Cell Lymphoma
    • Duarte, California
    • +2 more
    Oct 18, 2022

    Lymphoma, Mantle Cell Lymphoma Trial in Houston (Acalabrutinib, Rituximab, Brexucabtagene Autoleucel)

    Not yet recruiting
    • Lymphoma
    • Mantle Cell Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 10, 2022